Pharmacotherapy for obesity
Obesity is a serious, chronic, relapsing disease of energy regulation, with strong genetic and early-life environmental determinants.
Medications can be useful adjunct to lifestyle intervention in effecting and maintaining clincially significant weight loss in those with BMI >30, or 27-30 and obesity-related complications.
*Check BMI here.
Safety and efficacy should be monitored closely on commencement and the medication should be discontinued if there are safety or tolerability issues, or if <5% weight loss is observed after 3-4 months
For the majority of patients, following the exemplary diet and exercise recommendation provide only modest or no weight loss and difficulty to sustain.
Weight loss vs placebo (% or kg)
15, 30, 40 mg
3.6-4.5 kg in 6 months
Insomnia, dry mouth, agitation, tachicardia
Hypertension, glaucoma, history drug/alcohol abuse, SSRI antidepressants, pregnancy, heart disease
120 mg TDS
2.9-3.4% in 1 year
Steatorrhea, oil spotting, flatulence, incontinence, vitamin malabsorption
0.6 – 3
5.4% in 1 year
Nausea, Rare pancreatitis, cholecystitis
Renal/hepatic insufficiency, pregnancy, psychiatric disorder, past pancreatitis
4.8% in 1 year
Nausea, headache, dizzy and dry mouth
12.5 mg mane
25, 50, 100 mg
Insomnia, dry mouth, paraesthesia, altered taste, dizziness, depression
Glaucoma, renal stones, pregnancy
15 mg/12.5 mg mane
15/12.5- 100 mg
5-6.6% in 1 year
Bloating, diarrhea, Vit B12 deficiency, hypoglycemia
SGLT-2 (dapagliflozin, canagliflozin, empagliflozin)
1.8 – 2.7 kg
Genital and urinary tract infections